Biologics Contract Development and Manufacturing Company Grounded in high standards of quality and innovative technologies, LOTTE Biologics is committed to becoming a trusted partner for its customers while contributing to a better quality of life for patients worldwide.

Founded in 2022, the company entered the global Contract Development and Manufacturing Organization (CDMO) market through the acquisition of a biologics manufacturing facility in Syracuse, New York, and has since established global-standard manufacturing capabilities and robust quality management systems.
LOTTE Biologics is expanding its global manufacturing footprint through the development of a large-scale Bio Campus in the Songdo Bio Cluster in Incheon, South Korea. Building on this foundation, the company continues to broaden its business scope from antibody-based therapeutics to next-generation biopharmaceuticals, strengthening partnerships with global pharmaceutical companies through differentiated process development capabilities and a stable supply chain.